Nuvectis Pharma, Inc. (NVCT) Stock Price & Analysis
Nuvectis Pharma, Inc. (NVCT) rose 4.03% to USD 9.8 as of June 10, 2026 at 12:14 UTC, according to Nexqual real-time market data.
NVCT last closed at USD 9.42; the session ranged USD 9.35–9.86 on volume of 63,696 shares. Market capitalization is $259.95M, with a 52-week range of USD 5.55–13.34 (NCM). Source: Nexqual, June 10, 2026 at 12:14 UTC.
Key Statistics (as of June 10, 2026 at 12:14 UTC)
| Price | USD 9.8 |
|---|---|
| Change | ▲ 4.03% (up) |
| Previous Close | USD 9.42 |
| Open | USD 9.52 |
| Day Range | USD 9.35 – 9.86 |
| 52-Week Range | USD 5.55 – 13.34 |
| Volume | 63,696 shares |
| Market Cap | $259.95M |
| Exchange | NCM |
Technical Analysis (NVCT)
Nexqual's technical model rates NVCT "SELL" based on 2 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 12:14 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.85 (neutral) |
| vs SMA50 | Above (USD 9.31) |
| MACD | -0.04 (negative) |
Analyst Ratings (NVCT)
Wall Street analysts rate NVCT "None" based on 5 analysts, with a mean price target of USD 16.8 (range USD 10–20), per Nexqual as of June 10, 2026 at 12:14 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 16.8 |
| High Target | USD 20 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (NVCT)
| Next Earnings Date | 2026-08-04 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.26 vs est -0.31 ▲ beat |
| 2025-12-31 | USD -0.31 vs est -0.31 ▼ miss |
| 2025-09-30 | USD -0.44 vs est -0.25 ▼ miss |
| 2025-06-30 | USD -0.3 vs est -0.25 ▼ miss |
Source: Nexqual, June 10, 2026 at 12:14 UTC.
Financials & Fundamentals (NVCT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -154.43% |
| Current Ratio | 2.27 |
| Total Cash | $25.13M |
| Total Debt | $0 |
| Free Cash Flow | $-9.17M |
Source: Nexqual, June 10, 2026 at 12:14 UTC.
Financial Health Score (NVCT)
Nexqual rates Nuvectis Pharma, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 12:14 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $25M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$18M |
| Efficiency | Critical — ROE -154%, ROA -63.6% |
Ownership (NVCT)
| Insider Ownership | +41.61% |
|---|---|
| Institutional Ownership | +18.22% |
| Shares Outstanding | 26.53M |
| Float | 15.38M |
| Short % of Float | +10.14% |
Source: Nexqual, June 10, 2026 at 12:14 UTC.
Leadership (NVCT)
Nuvectis Pharma, Inc. is led by Ron Bentsur (age 59), Co-Founder, Chairman, CEO & President, per Nexqual as of June 10, 2026 at 12:14 UTC.
| Co-Founder, Chairman, CEO & President | Ron Bentsur (age 59) |
|---|---|
| Co-Founder, Executive VP, Chief Scientific & Business Officer | Enrique Poradosu (age 58) |
| Vice President of Finance | Michael Carson (age 49) |
Major Backers & Investors (NVCT)
Notable institutional backers of Nuvectis Pharma, Inc. include Iridian Asset Management LLC, Occam Crest Management LP, Baldwin Wealth Partners LLC/MA, according to Nexqual as of June 10, 2026 at 12:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Iridian Asset Management LLC | 2.46% |
| Occam Crest Management LP | 1.53% |
| Baldwin Wealth Partners LLC/MA | 1.43% |
| Fidelity | 1.03% |
| Susquehanna International Group, LLP | 0.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.66% |
| BlackRock | 4.8% |
| Geode Capital | 1.45% |
| State Street | 0.63% |
| Northern Trust | 0.47% |
Source: Nexqual, June 10, 2026 at 12:14 UTC.
From Nuvectis Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
- The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NRSN | NeuroSense Therapeutics Ltd. | USD 0.76 | ▲ 1.33% |
| IMMX | Immix Biopharma, Inc. | USD 8.01 | ▲ 1.01% |
| ANGH | Anghami Inc. | USD 4.3 | ▲ 22.86% |
| HOUR | Hour Loop, Inc. | USD 1.76 | ▼ 7.37% |
| TRDA | Entrada Therapeutics, Inc. | USD 6.37 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:14 UTC. This page is informational and not investment advice.